Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Lifts ALI HEALTH's TP to HKD4.7; Rating Kept Sell
Recommend 3 Positive 2 Negative 2 |
||||
|
||||
|
In May, UBS downgraded ALI HEALTH (00241.HK)'s rating, but since then ALI HEALTH's first-party platform sales growth has surpassed its forecasts, according to its research report. UBS attributed this performance to a structural shift from offline to online pharmaceutical supply rather than a strategic pivot towards first-party platforms or first-party pharmaceutical sales. The broker also believes that leading peers can profit early from this structural trend. ALI HEALTH's target price has been raised from HKD3.8 to HKD4.7, with a Sell rating remaining in place. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
